摘要
目的观察尼莫地平联合尼麦角林对于阿尔茨海默病患者的临床效果及其对患者血清中雌激素(E2)、低氧诱导因子-1α(HIF-1α)水平的影响。方法选取2015年6月-2018年3月于本院住院治疗的AD患者138例,按照随机数字表法分为对照组和观察组;对照组患者给予尼莫地平片,观察组在对照组的基础上给予尼麦角林片,经过3个月的治疗后比较2组患者的临床疗效及不良反应,观察2组患者治疗前后的Barthel指数、MMSE评分、E2、HIF-1α水平。结果治疗前2组患者Barthel指数、MMSE评分、E2、HIF-1α水平无明显差异(P>0.05);治疗3个月后2组患者的E2水平、Barthel指数、MMSE评分均显著升高(P<0.05),但观察组显著高于对照组(P<0.05);HIF-1α水平显著下降(P<0.05),且观察组显著低于对照组(P<0.05)。观察组与对照组的总有效率分别为94.20%及82.61%,2组比较差异显著(χ^2=4.520,P=0.033);两组不良反应发生率分别为7.250%和5.80%,2组比较无明显差异(χ^2=0.120,P=0.730)。结论尼莫地平联合尼麦角林治疗阿尔茨海默病具有良好的临床疗效,能改善患者的认知功能障碍,有效的缓解脑细胞的缺血缺氧症状,且安全性较高。
Objective To observe the clinical effect of nimodipine combined with niergoline on patients with Alzheimer’s disease and its effect on the serum level of E2,HIF-1α.Methods 138 AD patients who were hospitalized in our hospital from June 2015 to March 2018 were selected. According to the method of random digital table, it was divided into control group and observation group.The patients in the control group were treated with nimodipine tablets, and the patients in the observation group were given niergoline tablets on the basis of the control group. After 3 months of treatment, the clinical efficacy and adverse reactions of the two groups were compared. Barthel index and MMSE score were measured before and after treatment.Results Before treatment there was no significant difference in Barthel index and MMSE score between the two groups(P>0.05). After 3 months of treatment the level of E2 and the scores of Barthel index and MMSE were significantly increased in both groups(P<0.05), and the level of E2 and the scores of Barthel index and MMSE were significantly higher in the observation group than those in the control group(P<0.05). After 3 months of treatment The HIF-1α level decreased significantly(P<0.05), and The HIF-1α level of the observation group was significantly lower than that of the control group(P<0.05).The total effective rates of the observation group and the control group were 94.20% and 82.61% respectively, and there was a significant difference between the two groups(χ~2=4.520,P=0. 033).The incidence of adverse reactions in the two groups was 7.250% and 5.80% respectively, and there was no significant difference between the two groups(χ~2=0.120,P=0.730).Conclusion Nimodipine combined with niergoline had a good clinical effect on Alzheimer’s disease. It could improve the cognitive function of the patients and relieve the ischemic and hypoxic symptoms of brain cells.
作者
毛礼阳
邵春阳
Mao Liyang;Shao Chunyang(Second Department of Medicine, Yangzhou Friendship Hospital, Yangzhou 225261)
出处
《卒中与神经疾病》
2019年第3期313-316,共4页
Stroke and Nervous Diseases
